the only chump i see is you seman... who stated that exel will be TRADE under a dollar b/f the end of 2014... how did that prediction work out for you genius? honesty and integrity are definitely traits you do not have or else you wouldn't be here at this board spewing your nonsense after betting that you would never post here again if the price does not drop under 1 as you predicted. who's the chump now?
gizmo, short some more, time is running out. since you're so certain, short until it hurts. don't forget to sell as much naked calls as you can... time is running out.
dawe, you seem to be excluding an important point. what is the expected result for the control arm? from all the papers i've read, the control arm behaved as expected. which only means that all the treatment arms, not just the high dose, are behaving very differently than expected. when something like this happens, with this huge a magnitude and consistency, it is reasonable to expect the cause to be the drug even if the small trial was small. the fda knows this b/c they gave them breakthrough designation. your so call expert should know this also.
don't need you assurance... all you need to do as back up your talk by going short... unless you're either too poor or too scared... you're likely both.
the fda also gave mydicar breakthrough designation. and for those who don't know, that's basically the fda saying cupid 1 trail was well executed and provided strong clinical data showing meaningful drug efficacy for an unmet need.
ogut is talking out of his behind or his book. dude acts like an expert but all he is is some no name scientist who's done some work in heart failure. he's entitled to his opinion but let us not forget, it's just that... an opinion. and if you've seen enough of his post son investorshub, you'll know that like all of us, he's made is share of bad calls... and cldn will prove him wrong once again.
if drug approval was as black and white as you believe, than there would be no need for FDA Advisory Committee to help the fda interpret the data. if it was black and white, there would be difference of opinion which there always are... you kind of thinking is for grade schooler... speaking of, have you even graduated from high school?
there's no absolute when doing sensitivity analysis. same as there being no absolute when looking at trial data. everything is up for interpretation. you on the other hand seem to think in terms of only black and white.
you have shown us very clearly you have no clue on how "scientific research is done". if you've got a backbone, support your argument by shorting. talk is cheap and right now, you're full of hot air
the problem is in your head... the efficacy seen in the low and mid dose matters b/c they support the argument that the benefit seen in the high dose was not a fluke b/c it shows there is a correlation between dose and efficacy. also, during the sensitivity analysis, it was determined that "cardiovascular history (higher proportion of patients with coronary artery disease, hypertension, myocardial infarction in the placebo group versus
high-dose group) were not predictive of study results when analyses were stratified by these factors". what lies are you going to think up next?
than how do you explain the fact that the mid and low dose group performed better than placebo for the first 6 to 9 months compared to placebo since the mid and low dose group both have more coronary artery disease and myocardial infarction compared to placebo? or that the high group still showed strong efficacy after they removed the high risk patients from the control group? you can't can you?
it must not have occurred to you that being wrong is not something to be proud of. but in your case if you didn't take pride in what little consistency you have even if it's being consistently wrong, you would have nothing at all. So thump that chest and continue to tell use how you're going to win it big.
i'll even let you in on my position. i had about 300k at an average price of about 1.65. i recently sold 100k at around 2.5. i'm going to hold the remaining shares going into meteor readout since i expect the trial will not only meet it's primary endpoint but will exceed it by a wide margin. This success will elevate all debt concerns and the market cap for exel should pass 3 billion giving a stock price of at lease 15/share. At which point, i'm going to sell about 100k and will let the rest ride to see how much higher i'll go.
during all this excitement, i might just think back and wonder how can anyone miss such a great buying opportunity; at which point, i may think of you. If you're still around them, i'm sure i'll have a few good words to share with you.
seman, for some but not you, it is easy. for example, I'm already on the beach enjoying the spoils of my investments contrary to ignoring experts like you who only know how to fud. keep up the good work.
you sure is smart seman. I really like the result from the last time you said the stock price was definitely going under a dollar before the end of 2014. this time you should stick around when your prediction blows up in your face so we can try to comfort you.